Microcapsules for the synergistic delivery of probiotics and postbiotics from microfluidics for the treatment of colitis (I)

Bacterial metabolites have shown protective effects against colitis by regulating the gut microbiota, while the efficacy is limited by poor oral delivery efficiency and strict limitations on the use of single drugs. A novel synergistic delivery microcapsule of prebiotics and postbiotics has now been proposed, consisting of indole-3-propionic acid (IPA) postbiotics and three prebiotics: sodium alginate, resistant starch (RS), and chitosan. This microcapsule is used to prevent and treat colitis through microfluidic electrospray. The study found that oral administration of IPA microcapsules (IPA@MC) in mice has a significant protective effect against colitis, indicating the existence of a therapeutic synergistic effect between prebiotics and postbiotics. Furthermore, the mechanism of IPA@MC in regulating the gut microbiota significantly increases the overall abundance of bacteria that produce short-chain fatty acids (SCFAs), such as Faecalibacterium and Roseburia. These results suggest that the synergistic delivery microcapsules of prebiotics and postbiotics are ideal substances for treating colitis.

In this study, a novel prebiotic andpostbioticsynergistic delivery microcapsule is provided for the treatment of colitis. Prebiotics are indigestible dietary carbohydrates, including alginates, chitosan, inulin, etc., which have been widely used in diseases related to gut microbiota dysbiosis and as drug carriers. Postbiotics are small molecular metabolites other than prebiotics that play important roles in gut immune regulation, epithelial nutrition, and microbiota homeostasis. Among different postbiotics, tryptophan metabolites, including indole-3-propionic acid (IPA) and short-chain fatty acids (SCFAs), are the most attractive candidates for preventing and treating gastrointestinal diseases, including colitis, metabolic diseases, and cancer. A recent study also revealed that these metabolites regulate the gut barrier by modulating the gut microbiota, reducing inflammation by inhibiting HDAC and activating HAT in colon cells. However, studies have found that single postbiotics are insufficient to rebuild a healthy gut, leading to a low response to oral postbiotics for these diseases. Additionally, the oral delivery of water-soluble postbiotics suffers from low delivery efficiency in the gastrointestinal tract and limited overall therapeutic effects. This evidence suggests that the combined administration of prebiotics and postbiotics can help avoid colitis by increasing the abundance of beneficial bacteria produced by prebiotic fermentation in the gut and the levels of other postbiotics. Therefore, a more efficient and controllable delivery carrier for the combined administration of prebiotics and postbiotics is needed for the treatment of colitis. Microfluidics has been widely used to develop smart drug delivery systems. With advancements in microfluidic synthesis technology, lower molecular weight drugs can be encapsulated in prebiotic microcapsules, achieving controllable particle size distribution and formulation stability. These systems, such as microcapsules produced by microfluidics, can slow down the release of drugs in the acidic upper gastrointestinal tract after oral administration, thereby increasing the drug concentration in the lower gastrointestinal tract. Therefore, smart microfluidic microcapsules are believed to provide an effective venue for the combined delivery of prebiotics and postbiotics and offer a new platform for studying the synergistic effects of prebiotics and postbiotics in the treatment of colitis.

a) Microfluidic electrospray program for generating IPA-encapsulated Alg/RS microcapsules, which are further coated with chitosan. b) The dual pH-sensitive core-shell structure allows for slow drug release under acidic conditions in the upper gastrointestinal tract and rapid drug release under neutral conditions in the lower gastrointestinal tract, exerting protective effects against colitis by modulating the gut microbiota. Alg: alginate; RS: resistant starch; CS: chitosan; IPA: indole-3-propionic acid.

The required prebiotic microcapsules were generated using capillary microfluidic electrospray technology, and IPA postbiotics were encapsulated to prevent colitis. In vivo experiments showed that oral administration of IPA@MC provided significant protection against colitis compared to mice receiving prebiotics or postbiotics alone, indicating that the synergistic effect between prebiotics and postbiotics in IPA@MC offers a more effective treatment strategy for colitis. Additionally, the study indicated that IPA@MC can regulate the gut microbiome by significantly increasing the overall abundance and richness of bacteria that produce SCFAs, such as Faecalibacterium and Roseburia. Therefore, this synergistic delivery microcapsule of prebiotics and postbiotics is considered a promising candidate for the treatment of colitis.

Note: The article is translated from Prebiotics and Postbiotics Synergistic Delivery Microcapsules from Microfluidics for Treating Colitis.(For academic reference only)

Chuangyuan Biotechnology, probiotics, prebiotics, postbiotics, metabolites

Microcapsules for the synergistic delivery of probiotics and postbiotics from microfluidics for the treatment of colitis (Part II)

Atopic dermatitis and gut microbiota

Microcapsules for the synergistic delivery of probiotics and postbiotics from microfluidics for the treatment of colitis (Part II)

Atopic dermatitis and gut microbiota

2024-12-23

In December 2024, Tianjin Chuangyuan Biotechnology Co., Ltd. and Haihe Dairy jointly held a series of themed activities titled "Party Building Mutual Visits and Learning" to further promote the deep integration of both parties' party building work and business development. During the event, both sides will conduct company visits and on-site discussions. Recently, Haihe Dairy made an initial visit and, after gaining a deep understanding of Chuangyuan Biotech's products, expressed high recognition and close attention, laying a solid foundation for future cooperation. Subsequently, both parties engaged in detailed communication on the core topics of "exchange of party building experiences and sharing of business resources," discussing standardized construction of party branches, distinctive party building measures, and the promotion of party-business integration. They also conducted in-depth exchanges on aspects such as corporate cooperation, product intercommunication, and information sharing, jointly exploring new paths for the development of the health industry under the guidance of party building, providing more possibilities for further establishing a "symbiotic, mutually promoting, and win-win" cooperative relationship. Both parties hope to achieve industrial resonance through party building leadership and contribute to the development of the health industry in the Binhai New Area.

Strength crowned, Chuangyuan Biotechnology won two Science and Technology Awards from the China Food Industry Association.

2024-12-17

On December 16, 2024, the 22nd China Food Safety Conference and the 2024 National Food Industry Science and Technology Progress Conference, themed "Implementing Food Safety Strategy to Support the Construction of a Healthy China," was grandly held in Beijing. During the conference, the award ceremony for the 2024 National Food Industry Science and Technology Progress Conference was also held. Tianjin Chuangyuan Biotechnology Co., Ltd. won the second prize for scientific and technological progress in the "2023 China Food Industry Association Science and Technology Award" for two projects: "Key Technology Breakthrough and Industrial Application of New Postbiotics Segmented Solid-State Fermentation" and "Development and Application of Key Technologies and Equipment for Plant Polysaccharide Efficacy Verification and Extraction."

Chuangyuan Biotech's lactic acid bacteria IOB701 post-fermentation probiotic powder has been granted a national invention patent.

2024-12-13

On December 13, 2024, Tianjin Chuangyuan Biotechnology Co., Ltd. received an invention patent certificate from the National Intellectual Property Administration for its independently developed and filed method and application for the preparation of Lactobacillus plantarum IOB701 fermented postbiotics powder (Patent No.: ZL 202411354886.X). This invention provides a method and application for the preparation of Lactobacillus plantarum IOB701 fermented postbiotics powder, which relates to the field of microbiology. The Lactobacillus plantarum IOB701 was preserved on July 10, 2018, at the General Microbial Culture Collection Center of the China Microbial Strain Preservation Management Committee, abbreviated as CGMCC, with the preservation address at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number CGMCC No. 16077. Using grains or legumes treated with low oxygen stress as the fermentation substrate, the Lactobacillus plantarum IOB701 fermentation resulted in postbiotics powder, which, according to animal experiments, has been shown to improve chronic unpredictable mild stress-induced depressive-like behavior in mice.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Jin Gong Wang An Bei No. 12019202000539

Business License